A randomized, double-blind, placebo managed, period III medical trial evaluated the efficacy and safety profile of adalimumab for a monotherapy in individuals with RA who had failed to reply to csDMARDs [191]. The outcomes showed each statistically major enhancement from the disease action and a very good safety profile. However, https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/